Xeris Biopharma soars on premarket leading volume after FDA approval of Cushing's syndrome treatmentMarket Watch • 12/31/21
Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing's SyndromeBusiness Wire • 12/30/21
Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris PharmaBusiness Wire • 12/16/21
Xeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other HighlightsBusiness Wire • 11/10/21
Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021Business Wire • 11/02/21
Will Xeris Biopharma (XERS) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 11/01/21
Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitBusiness Wire • 09/17/21
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge BiopharmaBusiness Wire • 09/14/21
Xeris Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/07/21
Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)Business Wire • 09/01/21
Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge BiopharmaBusiness Wire • 08/30/21